

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Michael Raschke et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: September 24, 2003

Examiner: To be assigned

For: Use of Growth Hormone Or A Growth Hormone Secretagogue For Promoting Bone Formation

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 08/963,388 filed on November 3, 1997, and with Form PTO-892, the benefit of which is claimed under 35 USC 120.

The references are as follows:


1. WO 89/03695;
2. WO 95/14666;
3. WO 94/22463;
4. U.S. Patent 5,536,716;
5. U.S. Patent 5,769,850;
6. Abstract of G. Giebel, Orthopade, Vol. 24, No. 5, pgs. 436-440 (1995);
7. Bak et al., Clinical Orthopaedics and Related Research, No. 264, pgs. 295-301 (1991);
8. Bak et al., Bone, Vol. 11, pgs. 233-239 (1990);
9. Raschke et al., Bone, Vol. 24, pgs. 81-88 (1999);
10. Abstract of WO 96/623 (05/31/96); and
11. Windhagen et al., Complexity Endocr. Syst., [Symp.], pgs. 155-162 (1996).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Date: September 24, 2003

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No.
4951.220-USSerial No.
To be assignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicants:
Michael Raschke et al.Filing Date
September 3, 2003?Group
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,769,850	06/23/98	Martin Chin	606	53	10/16/96
	5,536,716	07/16/96	Chin et al.	514	215	11/03/93

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 89/03695	05/05/89	WIPO				
	WO 95/14666	06/01/95	WIPO				
	WO 94/22463	10/13/94	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bak et al., Clinical Orthopaedics and Related Research, No. 264, pgs. 295-301(1991)
		Abstract of G. Giebel, Orthopade, Vol. 24, No. 5, pgs. 436-440 (1995)
		Bak et al., Bone, Vol. 11, pgs. 233-239 (1990)
		Raschke et al., Bone, Vol. 24, pgs. 81-88 (1999)
		Abstract of WO 96/623 (05/31/96)
		Windhagen et al., Complexity Endocr. Syst.,]Symp.], pgs. 155-162 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPSP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.